BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19929252)

  • 1. Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.
    Filopanti M; Lania AG; Spada A
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):43-53. PubMed ID: 19929252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
    Filopanti M; Barbieri AM; Angioni AR; Colao A; Gasco V; Grottoli S; Peri A; Baglioni S; Fustini MF; Pigliaru F; Monte PD; Borretta G; Ambrosi B; Jaffrain-Rea ML; Gasperi M; Brogioni S; Cannavò S; Mantovani G; Beck-Peccoz P; Lania A; Spada A
    Pharmacogenomics J; 2008 Oct; 8(5):357-63. PubMed ID: 18332900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
    Bueno C; Trarbach EB; Bronstein MD; Glezer A
    Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
    Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
    Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
    Ilhan M; Kahraman OT; Turan S; Turgut S; Karaman O; Zeybek U; Shukurov S; Yaylim I; Tasan E
    Ann Endocrinol (Paris); 2015 Oct; 76(5):614-9. PubMed ID: 26514951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
    Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
    Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
    Paus S; Grünewald A; Klein C; Knapp M; Zimprich A; Janetzky B; Möller JC; Klockgether T; Wüllner U
    Mov Disord; 2008 Mar; 23(4):599-602. PubMed ID: 18175338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polymorphism of the dopamine D2 receptor gene in populations from the Volga-Ural region].
    Galeeva AR; Iur'ev EB; Khusnutdinova EK
    Genetika; 2000 Oct; 36(10):1394-400. PubMed ID: 11094753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family-based and case-control study of DRD2, DAT, 5HTT, COMT genes polymorphisms in alcohol dependence.
    Samochowiec J; Kucharska-Mazur J; Grzywacz A; Jabłoński M; Rommelspacher H; Samochowiec A; Sznabowicz M; Horodnicki J; Sagan L; Pełka-Wysiecka J
    Neurosci Lett; 2006 Dec; 410(1):1-5. PubMed ID: 17079080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk.
    Gemignani F; Landi S; Moreno V; Gioia-Patricola L; Chabrier A; Guino E; Navarro M; Cambray M; Capellà G; Canzian F
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1633-8. PubMed ID: 16030094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
    Miller DK; Bowirrat A; Manka M; Miller M; Stokes S; Manka D; Allen C; Gant C; Downs BW; Smolen A; Stevens E; Yeldandi S; Blum K
    Postgrad Med; 2010 Nov; 122(6):188-213. PubMed ID: 21084795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a high-throughput method for screening the dopamine D2 (DRD2) receptor gene polymorphisms based on the LightCycler system.
    Stefan P; Moritz E; Alexander W; Weber M; Norbert D; Annette W; Thomas F; Andreas P
    Clin Lab; 2009; 55(9-10):353-8. PubMed ID: 20099571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the DRD2 gene haplotype and its association with alcoholism in Mexican Americans.
    Luo HR; Hou ZF; Wu J; Zhang YP; Wan YJ
    Alcohol; 2005 Jun; 36(2):117-25. PubMed ID: 16396745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan.
    Wang TJ; Huang SY; Lin WW; Lo HY; Wu PL; Wang YS; Wu YS; Ko HC; Shih JC; Lu RB
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):108-14. PubMed ID: 17007976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
    Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
    Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No association of dopamine receptor sensitivity in vivo with genetic predisposition for alcoholism and DRD2/DRD3 gene polymorphisms in alcohol dependence.
    Wiesbeck GA; Dürsteler-MacFarland KM; Wurst FM; Walter M; Petitjean S; Müller S; Wodarz N; Böning J
    Addict Biol; 2006 Mar; 11(1):72-5. PubMed ID: 16759339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype combinations for monoamine oxidase-B intron 13 polymorphism and dopamine D2 receptor TaqIB polymorphism are associated with ever-smoking status among men.
    Costa-Mallen P; Costa LG; Checkoway H
    Neurosci Lett; 2005 Sep; 385(2):158-62. PubMed ID: 15955630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of interaction between a polymorphism in the dopamine D2 receptor gene and the clinical features of migraine.
    Rebaudengo N; Rainero I; Parziale A; Rosina F; Pavanelli E; Rubino E; Mazza C; Ostacoli L; Furlan PM
    Cephalalgia; 2004 Jun; 24(6):503-7. PubMed ID: 15154861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.
    Crettol S; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Déglon JJ; Preisig M; Eap CB
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1722-7. PubMed ID: 18687376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.